Calgary-based firm CardiAL has received approval to begin trials of therapeutics in COVID-19 patients. The company will be conducting two trials, hospitalized and non-hospitalized patients, with the outpatient cohort receiving colchicine and Aspirin and the inpatient group receiving both drugs plus rivaroxaban, an anticoagulant. The two trials will look to compare disease progression and mortality. Researchers hope to enroll 4,000 patients and complete the work by June 30.